BC Innovations | May 15, 2019
Distillery Therapeutics

Inhibiting PIM2 sensitizes CML to Gleevec

DISEASE CATEGORY: Cancer INDICATION: Chronic myelogenous leukemia (CML) Patient sample, cell culture and mouse studies suggest inhibiting PIM2 could sensitize CML to the dual BCR-ABL/c-Kit inhibitor Gleevec imatinib. In CML patients, levels of PIM2 mRNA...
BC Innovations | Aug 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: July 2018

New Therapeutic Targets and Biomarkers: July 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2018. Therapeutic targets are defined as any protein, gene or other...
BC Innovations | Jul 24, 2018
Distillery Therapeutics

Cardiovascular

INDICATION: Hypertension In vitro and mouse studies identified a pyrazolopyrimidinone-based DAPK3/pan-PIM inhibitor that could help treat hypertension. Chemical synthesis and in vitro activity testing of analogs of a pyrazolopyrimidinone-based compound identified a molecule that inhibited...
BC Innovations | Jun 29, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: June 2017

New Therapeutic Targets and Biomarkers: June 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during June 2017. Therapeutic targets are defined as any protein, gene or other...
BC Innovations | Jun 7, 2017
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest jointly inhibiting PI3K and either PIM2 , TACC1 , ZAK , ZFR or ZNF565 could help treat breast cancer. An shRNA screen in a human breast cancer cell line...
BC Innovations | Jun 30, 2016
Distillery Therapeutics

Therapeutics: Pim-1 (PIM1); Pim-2 (PIM2)

Cancer INDICATION: Multiple myeloma (MM) In vitro and mouse studies identified a quinazolinone-based inhibitor of PIM1 and PIM2 that could help treat MM. Chemical synthesis and in vitro testing of quinazolinone-pyrrolopyrrolone analogs yielded one compound...
BC Week In Review | Jun 10, 2013
Company News

Jasco Pharmaceuticals, Roswell Park Cancer Institute deal

Jasco and Roswell Park partnered to jointly conduct preclinical testing of Jasco's cancer compound JP-11646 , including pharmacokinetic and pharmacodynamics analysis. The project will utilize Roswell Park's Center for Drug Development. Jasco will fund the collaboration...
BC Week In Review | Apr 15, 2013
Clinical News

Jasco Pharmaceuticals preclinical data

In an animal xenograft model of MM, twice-daily 30 mg/kg oral JP-11646 inhibited tumor growth by 82% vs. vehicle-treated controls. In MM cell lines with chromosome translocations known for poor prognosis, JP-11646 increased apoptosis and...
BC Innovations | Sep 15, 2011
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Non-Hodgkin's lymphoma (NHL) Pim-2 (PIM2); eukaryotic translation initiation factor 4A1 (EIF4A1) Patient tissue and mouse studies suggest protein translation inhibitors could help treat chemoresistant PIM2-expressing...
BC Week In Review | Mar 14, 2011
Company News

Jasco Pharmaceuticals, North Carolina Central University deal

The biotech and university will collaborate to develop therapeutics for pancreatic cancer using Jasco's preclinical selective Pim-1 (PIM1) , PIM2 and PIM3 kinase inhibitors. Further terms were not disclosed. Jasco Pharmaceuticals LLC , Woburn, Mass.   North...
Items per page:
1 - 10 of 11